CORE LABORATORIES N V Quarterly Contract with Customer, Liability, Current in USD from Q4 2017 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
Summary
Core Laboratories N V quarterly Contract with Customer, Liability, Current history and growth rate from Q4 2017 to Q1 2023.
  • Core Laboratories N V Contract with Customer, Liability, Current for the quarter ending March 31, 2023 was $794K, a 61.5% decline year-over-year.
Contract with Customer, Liability, Current, Quarterly (USD)
Contract with Customer, Liability, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2023 $794K -$1.27M -61.5% Mar 31, 2023 10-Q 2023-04-27
Q4 2022 $907K -$393K -30.2% Dec 31, 2022 10-Q 2023-04-27
Q3 2022 $885K -$434K -32.9% Sep 30, 2022 10-Q 2022-10-28
Q2 2022 $1.35M +$184K +15.8% Jun 30, 2022 10-Q 2022-07-28
Q1 2022 $2.06M +$988K +92% Mar 31, 2022 10-Q 2022-04-28
Q4 2021 $1.3M +$347K +36.4% Dec 31, 2021 10-K 2023-02-10
Q3 2021 $1.32M -$239K -15.3% Sep 30, 2021 10-Q 2021-10-29
Q2 2021 $1.17M -$1.19M -50.6% Jun 30, 2021 10-Q 2021-07-30
Q1 2021 $1.07M -$2.56M -70.5% Mar 31, 2021 10-Q 2021-04-23
Q4 2020 $953K -$3.52M -78.7% Dec 31, 2020 10-K 2022-02-10
Q3 2020 $1.56M -$2.37M -60.3% Sep 30, 2020 10-Q 2020-10-22
Q2 2020 $2.36M -$4.02M -63% Jun 30, 2020 10-Q 2020-07-24
Q1 2020 $3.64M -$3.96M -52.1% Mar 31, 2020 10-Q 2020-04-24
Q4 2019 $4.47M -$1.49M -25% Dec 31, 2019 10-K 2021-02-08
Q3 2019 $3.93M -$914K -18.9% Sep 30, 2019 10-Q 2019-10-25
Q2 2019 $6.38M +$1.84M +40.6% Jun 30, 2019 10-Q 2019-07-26
Q1 2019 $7.6M +$3.67M +93.6% Mar 31, 2019 10-Q 2019-04-26
Q4 2018 $5.96M +$3.71M +165% Dec 31, 2018 10-K 2020-02-10
Q3 2018 $4.84M Sep 30, 2018 10-Q 2018-10-25
Q2 2018 $4.54M Jun 30, 2018 10-Q 2018-07-27
Q1 2018 $3.92M Mar 31, 2018 10-Q 2018-04-27
Q4 2017 $2.25M Dec 31, 2017 10-K 2019-02-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.